好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal Evaluation and Optimization of the Parkinson’s Disease-health Index: A Disease-specific Patient-reported Outcome Measure for Parkinson’s Disease Clinical Trials
Movement Disorders
S37 - Movement Disorders: Clinical Trials (2:48 PM-3:00 PM)
010

We previously developed and validated the PD-HI in accordance with FDA guidelines using large-scale patient data. This two-year natural history study will obtain longitudinal metrics of the instrument and identify faster or slower disease progression among demographic and clinical subgroups.

To further validate the Parkinson’s Disease-Health Index (PD-HI), a patient-reported outcome (PRO) measure for serially tracking disease burden in Parkinson’s disease (PD).

Adults with PD are participating in a 24-month longitudinal study, completing assessments at baseline, 6, 12, 18, and 24 months. At each time point, participants are completing the PD-HI, NeuroQol, and parts Ib and II of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). During the 6-24 month assessments, participants are asked to respond to a global impression of change survey and complete a survey preference form. This data will determine the responsiveness of the PD-HI for detecting therapeutic gains, determine the minimal clinical important difference (MCID) for the instrument and its subscales, and inform participant PRO preferences. The natural history data collected will provide insight on PD symptom progression for various demographic and clinical subgroups.

One hundred and ninety-nine individuals with PD were enrolled and 128 individuals completed all baseline and 6-month assessments. Participants are currently completing 12-month assessments. The PD-HI and six of its subscales detected a statistically significant change in disease burden over 6 months; only one of 13 Neuro-QoL subscales detected a statistically significant change in PD health over 6 months. All PD-HI subscales correlated with baseline MDS-UPDRS scores.

The PD-HI is capable of detecting clinically meaningful changes in disease burden over time. Forthcoming data will identify demographic and clinical subgroups associated with various symptom progression, obtain instrument performance metrics to maximize clinical trial efficiency, and further evaluate the responsiveness of the PD-HI compared to other PROs.

Authors/Disclosures
Chad R. Heatwole, MD, FAAN (University of Rochester Medical Center)
PRESENTER
Dr. Heatwole has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Virginia Commonwealth University. Dr. Heatwole has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Legal Med. Dr. Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Swan Bio. Dr. Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Harmony. Dr. Heatwole has received personal compensation in the range of $0-$499 for serving as a Consultant for Iris. Dr. Heatwole has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Recursion. Dr. Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avidity Biosciences. Dr. Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lupin. Dr. Heatwole has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurocrine. Dr. Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Heatwole has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for New York Central Mutual. Dr. Heatwole has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Penn Prop and Gas. The institution of Dr. Heatwole has received research support from Department of Defense. The institution of Dr. Heatwole has received research support from Novartis. The institution of Dr. Heatwole has received research support from MJFF. The institution of Dr. Heatwole has received research support from FARA. The institution of Dr. Heatwole has received research support from NIH. The institution of Dr. Heatwole has received research support from University of Miami. The institution of Dr. Heatwole has received research support from MDA. Dr. Heatwole has received intellectual property interests from a discovery or technology relating to health care.
Charlotte Irwin Ms. Irwin has nothing to disclose.
Jamison Seabury (University of Rochester) Jamison Seabury has nothing to disclose.
Charlotte Engebrecht (University of Rochester Center for Health + Technology) Ms. Engebrecht has nothing to disclose.
Jennifer Weinstein Jennifer Weinstein has nothing to disclose.
Anika Varma (Center for Health + Technology, University of Rochester) Anika Varma has nothing to disclose.
Spencer Rosero (University of Rochester, Center for Health and Technology) Spencer Rosero has nothing to disclose.
Christina Shupe (Center for Health and Technology, University of Rochester) Ms. Shupe has nothing to disclose.
Preshetha Kanagaiah (University of Rochester Center for Health and Technology) Miss Kanagaiah has nothing to disclose.
Judith Monickaraj, MS Ms. Monickaraj has nothing to disclose.
John Heatwole (39465) An immediate family member of John Heatwole has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for legal med. An immediate family member of John Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for neurocrine. An immediate family member of John Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartis. An immediate family member of John Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for swan bio. An immediate family member of John Heatwole has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for recursion. An immediate family member of John Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for sanofi. An immediate family member of John Heatwole has received personal compensation in the range of $500-$4,999 for serving as a Consultant for lupin. An immediate family member of John Heatwole has received personal compensation in the range of $0-$499 for serving as a Consultant for vertex. The institution of an immediate family member of John Heatwole has received research support from dod. The institution of an immediate family member of John Heatwole has received research support from novartis. The institution of an immediate family member of John Heatwole has received research support from mjff. The institution of an immediate family member of John Heatwole has received research support from fara. The institution of an immediate family member of John Heatwole has received research support from nih. The institution of an immediate family member of John Heatwole has received research support from unviversity of miami. The institution of an immediate family member of John Heatwole has received research support from mda. An immediate family member of John Heatwole has received intellectual property interests from a discovery or technology relating to health care.
Abigail Arky Abigail Arky has nothing to disclose.
Christine Zizzi (University of Rochester Medical Center, Center for Health + Technology (CHeT)) No disclosure on file
Nuran Dilek (University of Rochester) Nuran Dilek has nothing to disclose.
Jennifer L. Purks, MD (University of Rochester/Strong Memorial Hospital) Dr. Purks has received research support from The Michael J. Fox Foundation.
Jamie L. Adams, MD (University of Rochester Medical Center) Dr. Adams has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Adams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Michael J. Fox Foundation. Dr. Adams has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BioSensics. The institution of Dr. Adams has received research support from NIH/NINDS. The institution of Dr. Adams has received research support from Biogen. The institution of Dr. Adams has received research support from The Michael J. Fox Foundation. The institution of Dr. Adams has received research support from Critical Path Institute. Dr. Adams has received personal compensation in the range of $500-$4,999 for serving as a KINECT-HD Steering Committee Member with Huntington Study Group. Dr. Adams has received personal compensation in the range of $500-$4,999 for serving as a ORCHESTRA-PD Steering Committee Member with Parkinson Study Group.
E. Ray Dorsey, MD, MBA (University of Rochester) Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seelos Therapeutics. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eden McCallum, LLP. Dr. Dorsey has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech/Roche. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for WebMD. Dr. Dorsey has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BioSensics. Dr. Dorsey has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Mediflix. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevance. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kairos Cinema, LLC. Dr. Dorsey has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America Inc.. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HanAll. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Dorsey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Advarra. Dr. Dorsey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medrhythms. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ANA. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for HMP 好色先生, LLP. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ADIVO Associates France. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for University of Toronto. Dr. Dorsey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philadelphia Neurological Society. Dr. Dorsey has stock in Included Health. Dr. Dorsey has stock in Mediflix. Dr. Dorsey has stock in SemCap. Dr. Dorsey has stock in Synapticure. The institution of Dr. Dorsey has received research support from NIH/NINDS. The institution of Dr. Dorsey has received research support from Burroughs Wellcome . The institution of Dr. Dorsey has received research support from Michael J. Fox Foundation - Fox Insight. The institution of Dr. Dorsey has received research support from Michael J. Fox Foundation - Emerald. The institution of Dr. Dorsey has received research support from B. Thomas Golisano Foundation. The institution of Dr. Dorsey has received research support from Emerald Innovations, Inc.. The institution of Dr. Dorsey has received research support from Photopharmics Inc.. The institution of Dr. Dorsey has received research support from Averitas Pharma Inc.. The institution of Dr. Dorsey has received research support from DOD/Army Medical Research Acquisition Activity. The institution of Dr. Dorsey has received research support from NIH/NINDS.